The Effect of Feeding Infant Formula With Enriched Protein Fractions in the US
The Effect of Feeding Infant Formula With Enriched Protein Fractions
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Kannapolis, North Carolina, United States, 28081
- University or North Carolina Nutrition Research Instutite
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Singleton, 0-90 days of age at randomization
- Term infant with birth weight of a minimum of 2500 grams
- Receiving at least 75% of the recommended caloric intake from cow's milk-based infant formula
- Parent or legally authorized representative attending study visits reads, understands, and speaks English
- Signed Informed Consent and Protected Health Information authorization
Exclusion Criteria:
- History of underlying metabolic or chronic disease, congenital malformation, or immunocompromised
- Feeding difficulties or formula intolerance
- Infant born small for gestational age
- Infant born from a mother who was diabetic at childbirth
- History of seizures or neurological disorders or infant with known head/brain disease/injury
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Cow's milk-based infant formula
|
|
|
Experimental: Cow milk-based infant formula with enriched protein fractions
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sequence Recall using 3-dimensional props
Time Frame: 365 days of age
|
365 days of age
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Electroencephalogram response to stimuli
Time Frame: 180 days of age
|
180 days of age
|
|
Sequence Recall using 3-dimensional props
Time Frame: 300 days of age
|
300 days of age
|
|
Infant Behavior Questionnaire Revised, Short
Time Frame: 240 days of age
|
240 days of age
|
|
MacArthur-Bates Communication Development Inventory
Time Frame: 365 days of age
|
365 days of age
|
|
Bayley Scales of Infant and Toddler Development, Third Edition
Time Frame: 365 days of age
|
365 days of age
|
|
Achieved Weight
Time Frame: 52 weeks
|
52 weeks
|
|
Achieved Length
Time Frame: 52 weeks
|
52 weeks
|
|
Achieved Head Circumference
Time Frame: 52 weeks
|
52 weeks
|
|
Formula Intake
Time Frame: 52 weeks
|
52 weeks
|
|
Medically-confirmed Adverse Events
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 6035
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Declarative Memory
-
NCT02202629UnknownChange in Cognitive Function and Fatigue During Extended Performance of the Cognitive Demand Battery (CDB) at 1, 3 and 6 Hours Post Consumption | Change in Long Term Declarative Memory at 1, 3 and 6 Hours Post-intervention.
-
NCT04783740CompletedWorking Memory | The Working Memory Questionnaire
-
NCT01321021CompletedMemory, Short-Term | Memory, Long-Term
-
NCT07597603Not yet recruitingMemory | Habits | Behavior Change Interventions | Memory Encoding
-
NCT07020494Completed
-
NCT00142493CompletedMemory Losses | Amnesia-Memory Loss
-
NCT04598945Unknown
-
NCT01007682Completed
-
NCT02745522CompletedOxytocin Effect on Memory Performance During Phase 1 | Oxytocin Effect on Memory Performance During Phase 2 | Oxytocin Effect on Memory Performance During Phase 3 | Oxytocin Effect on Memory Performance During Phase 4
Clinical Trials on Cow's milk-based infant formula
-
NCT07342972Not yet recruitingInfections | Quality of Life | Gastrointestinal Tolerance | Gastrointestinal Symptoms | Anthropometrics
-
NCT06395571CompletedGastrointestinal Diseases | Infant Nutrition Disorders
-
NCT02860026Withdrawn
-
NCT02118935CompletedBehavioral Measures of Tolerance
-
NCT06744699Active, not recruitingGrowth | Infection | Gastrointestinal Symptoms | Allergy Symptoms
-
NCT06301139CompletedGastrointestinal Diseases | Cow's Milk Intolerance
-
NCT02776592CompletedChild Nutrition Sciences
-
NCT06108401Not yet recruitingGastrointestinal Diseases | Infant Nutrition Disorders
-
NCT02948114Terminated